Literature DB >> 25586333

A comparison of patients diagnosed with pulmonary embolism who are ≥65 years with patients <65 years.

Philip Cefalo1, Ido Weinberg2, Beau M Hawkins3, Praveen Hariharan4, Ikenna Okechukwu4, Blair A Parry4, Yuchiao Chang5, Rachel Rosovsky6, Shan W Liu4, Michael R Jaff2, Christopher Kabrhel7.   

Abstract

Recent studies have highlighted differences in how older patients respond to high-risk pulmonary embolism (PE) and treatment. However, guidelines for PE risk stratification and treatment are not based on age, and data are lacking for older patients. We characterized the impact of age on clinical features, risk stratification, treatment, and outcomes in a sample of patients with PE in the emergency department. We performed an observational cohort study of 547 consecutive patients with PE in the emergency department from 2005 to 2011 in an urban tertiary hospital. We used bivariate proportions and multivariable logistic regression to compare clinical presentation, risk category, treatment, and outcomes in patients ≥65 years with those <65 years. The mean age was 58 ± 17 years, 276 (50%) were women, and 210 (38%) were ≥65 years. PE was more severe in patients ≥65 years (massive 14% vs 5%, submassive 48% vs 25%, and low risk 38% vs 70%, p <0.0001), with submassive PE being the most common presentation in patients ≥65 years. However, subanalysis removing natriuretic peptides from the definition of submassive PE negated this finding. Treatment with parenteral anticoagulation (88% vs 90%, p = 0.32), thrombolytic therapy (5% vs 4%, p = 0.87), and inferior vena cava filter (4% vs 4%, p = 0.73) were similar among age groups. Patients ≥65 years had higher 30-day mortality (11% vs 3%, p <0.001). In conclusion, patients ≥65 years present with more severe PE and have higher mortality, although treatment patterns were similar to younger patients. Age-specific guideline definitions of submassive PE may better identify high-risk patients.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25586333     DOI: 10.1016/j.amjcard.2014.12.025

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Comorbidity assessment as predictor of short and long-term mortality in elderly patients with hemodynamically stable acute pulmonary embolism.

Authors:  Hernan Polo Friz; Valeria Corno; Annalisa Orenti; Chiara Buzzini; Chiara Crivellari; Francesco Petri; Melisa Polo Friz; Veronica Punzi; Daniela Teruzzi; Luca Cavalieri d'Oro; Cristina Giannattasio; Giuseppe Vighi; Claudio Cimminiello; Patrizia Boracchi
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

2.  Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settings.

Authors:  Jeffrey Trocio; Virginia M Rosen; Anu Gupta; Oluwaseyi Dina; Lien Vo; Patrick Hlavacek; Lisa Rosenblatt
Journal:  Clinicoecon Outcomes Res       Date:  2018-12-19

3.  Efficacy of rivaroxaban for the treatment of Chinese patients with acute pulmonary embolism: A retrospective study.

Authors:  Lei Wang; Shuang Jiang; Chao Li; Zhi Xu; Ying Chen
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

4.  Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years.

Authors:  Luis Jara-Palomares; Maria Alfonso; Ana Maestre; David Jimenez; Fernando Garcia-Bragado; Carme Font; Raquel Lopez Reyes; Luis Hernandez Blasco; Gemma Vidal; Remedios Otero; Manuel Monreal
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.